Clinical Evaluation of the SEQureDx T21 Test In High Risk Pregnancies

CompletedOBSERVATIONAL
Enrollment

3,062

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

October 31, 2014

Study Completion Date

December 31, 2015

Conditions
Down SyndromeFetal Aneuploidy
Trial Locations (29)

21201

University of Maryland, Baltimore

33029

Southeast Perinatal Associates - Miramar, Miramar

33175

South Florida Perinatal, Miami

33323

Southeast Perinatal Associates - Weston, Sunrise

37403

Regional Obstetrical Consultants, Chatanooga

40207

Norton Healthcare, Louisville

43231

Complete Healthcare for Women, Columbus

45267

University of Cincinnati, Cincinnati

48073

William Beaumont Hospital, Royal Oak

52242

University of Iowa Health Care, Iowa City

64111

Saint Lukes Hospital of Kansas City, Kansas City

66160

University of Kansas Medical Center, Kansas City

71118

Willis-Knighton Physician Network, Shreveport

73104

University of Oklahoma Health Sciences Center, Oklahoma City

85712

Visions Clinical Research Tuscon, Tucson

90048

Cedars-Sinai Medical Center, Los Angeles

90806

Long Beach Memorial Medical Center, Long Beach

91754

San Gabriel Valley Perinatal Medical Center, Monterey Park

92130

Scripps Clinic Carmel Valley, San Diego

95008

Obstetrix Medical Group of California, Campbell

96813

Hawaii Pacific Health, Honolulu

98104

Obstetrix Medical Group of Washington, Inc., Seattle

36604-3302

University of South Alabama, Mobile

07753

Jersey Shore University Medical Center, Neptune City

08901

Saint Peter's Hospital, New Brunswick

08080

Virtua Health, Sewell

08043

Virtua Health, Voorhees Township

Unknown

North York General Hospital, Toronto

G1V 4G2

Chuq/Chul, Québec

All Listed Sponsors
lead

Sequenom, Inc.

INDUSTRY

NCT01555346 - Clinical Evaluation of the SEQureDx T21 Test In High Risk Pregnancies | Biotech Hunter | Biotech Hunter